Bishal Gyawali, MD, PhD, Queen’s University Cancer Research Institute (Canada), joins the show to discuss the measurement of clinical benefit of new therapies and optimizing clinical trial design. Dr. Gyawali recaps a presentation he gave at last year’s ESMO Annual Meeting on clinical trial characteristics leading to artificial improvement of ESMO-MCBS scores for cancer drugs, goes on to list in detail the ten trial design characteristics that inflate the scores (including the use of surrogate endpoints and quality of life reporting, among others), and wraps up with a comment on future opportunities for clinical trial reform.
View Dr. Gyawali’s recent publication on clinical trial design: https://www.esmoopen.com/article/S2059-7029(21)00075-2/fulltext
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
